mProX™ Human NTRK3 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Kinase Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human NTRK3 Stable Cell Line (S01YF-1023-PY119). Click the button above to contact us or submit your feedback about this product.
Alex Williams (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Cameron Williams (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 The reduction of NTRK3 expression and diminished cell viability in DSRCT cell lines is observed as a consequence of NTRK3 shRNA knockdown, as depicted in the left and middle panels, while no such effect is noted in the Ewing cell line, as illustrated in the right panel.
To ascertain that the diminished viability was attributable to the inhibition of NTRK3 by entrectinib and repotrectinib, NTRK3 was targeted for suppression using two effective short hairpin RNAs (shRNA) in JN-DSRCT-1, SK-DSRCT-2, and CHP100 cells. Nonetheless, a reduction in viability was exclusively observed in the two DSRCT cell lines, indicating the indispensability of NTRK3 for DSRCT cell growth.
Ref: Ogura, Koichi, et al. "Therapeutic potential of NTRK3 inhibition in desmoplastic small round cell tumor." Clinical Cancer Research 27.4 (2021): 1184-1194.
Pubmed: 33229458
DOI: 10.1158/1078-0432.CCR-20-2585
Research Highlights
Lin, Ruihe. et al. "Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy." Diagnostic pathology, 2023.
The three NTRK genes have been extensively studied, with NTRK2 being the most complex in terms of its structural features. It has been linked to the development of various types of tumors. In adult soft tissue tumors, only STRN and RBPMS have been identified as fusion partners with NTRK2. Nevertheless, the selective Trk tyrosine kinases inhibitors, like larotrectinib and entrectinib, have demonstrated promising results in treating NTRK fusion-positive tumors and have received FDA approval.
Lin, Ruihe. et al. "Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy." Diagnostic pathology, 2023.
Pubmed:
37865792
DOI:
10.1186/s13000-023-01400-1
Donati, Michele. et al. "Spitz tumor with RAF1 fusion: A report of 3 cases." Annals of diagnostic pathology, 2023.
The study discusses Spitz tumors, a type of melanocytic neoplasm, and their characteristic features such as spindled and/or epithelioid cells, specific stromal and epidermal changes, and fusion kinases associated with ALK, ROS1, NTRK1, NTRK2, NTRK3, MET, RET, BRAF, and MAP3K8 genes. Recently, RAF1 fusions have also been identified in cutaneous melanocytic neoplasms. The researchers present three cases of Spitz neoplasms with a RAF1 fusion, including one previously reported fusion and two novel fusions. These findings suggest that RAF1 fusion may serve as an oncogenic driver in a subset of Spitz tumors.
Donati, Michele. et al. "Spitz tumor with RAF1 fusion: A report of 3 cases." Annals of diagnostic pathology, 2023.
Pubmed:
37856952
DOI:
10.1016/j.anndiagpath.2023.152215
